Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Eleonora Ghisoni, Alexandre Wicky, Hasna Bouchaab, +22

European Journal of Cancer

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function

Matteo Morotti, Alizée J Grimm, Helen Carrasco Hope, +38

Nature

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

Marine Bruand, David Barras, Marco Mina, +32

Cell Reports

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 ⁺ T-myeloid cell networks in melanoma

David Barras, Eleonora Ghisoni, Johanna Chiffelle, +42

Science Immunology

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Johanna Chiffelle, David Barras, Rémy Pétremand, +29

Immunity

Radiation OncologyCancer ImmunosurveillanceT-regulatory CellMelanomaImmunology +9

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience

Eleonora Ghisoni, Dionyssios Katsaros, Furio Maggiorotto, +12

Journal of Ovarian Research

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Eleonora Ghisoni, Furio Maggiorotto, Fulvio Borella, +11

Journal of Ovarian Research

Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.

Paolo A. Ascierto, Reinhard Dummer, Caroline Gaudy‐Marqueste, +10

Journal of Clinical Oncology

Median DurationImmunologyImmunoeditingImmunotherapeuticsDermatology +15

Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study

Laura Marandino, Federica Trastu, Eleonora Ghisoni, +16

BMJ Oncology

Androgen receptor status predicts development of brain metastases in ovarian cancers

Gloria Mittica, Rebecca Senetta, Giulia Scotto, +11

Oncotarget